We report a collection of data about early breast cancer in male patients from 13 Italian institutions.
Methods and study design
We obtained data from patient charts and performed statistical analysis. The primary end points were overall survival and disease-free survival.
Results
A total of 205 men with invasive breast cancer was identified, with a median age of 66 years. Pathological characteristics were heterogeneous for T stage, N stage and HER2 status. Histological subtype was predominantly ductal infiltrating carcinoma. Most of them were hormone receptor positive. Mastectomy was the most common strategy. Postsurgical treatment was not standardized. Patients with large tumors were more likely to be treated with chemotherapy. Disease recurrence was associated with an ER+ and PR+ status.
Conclusions
We identified a correlation between relapse and hormone receptor expression, as is the case in female breast cancer.
FentimanI.S., FourquetA., HortobagyiG.N.: Male breast cancer. Lancet, 367: 595–604, 2006.
2.
SiegelR., NaishadhamD., JemalA.: Cancer statistics. 2012. CA Cancer J Clin, 62: 10–29, 2012.
3.
GiordanoS.H., CohenD.S., BuzdarA.U., PerkinsG., HortobagyiG.N.: Breast carcinoma in men: a population-based study. Cancer, 101: 51–57, 2004.
4.
AndersonW.F., JatoiI., TseJ., RosenbergP.S.: Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol, 28: 232–239, 2010.
5.
RibeiroG.G., SwindellR., HarrisM., BanerjeeS.S., CramerA.: A review of the management of the male breast carcinoma based on an analysis of 420 treated cases. Breast, 5: 141–146, 1996.
6.
CutuliB., Le-NirC.C., SerinD., KirovaY., GaciZ., LemanskiC., De LafontanB., ZoubirM., MaingonP., MignotteH., de LaraC.T., EdelineJ., Penault-LlorcaF., RomestaingP., DelvaC., CometB., BelkacemiY.: Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol, 73: 246–254, 2010.
7.
HammondM.E., HayesD.F., WolffA.C., ManguP.B., TeminS.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract, 6: 195–197, 2010.
8.
WolffA.C., HammondM.E., SchwartzJ.N., HagertyK.L., AllredD.C., CoteR.J., DowsettM., FitzgibbonsP.L., HannaW.M., LangerA., McShaneL.M., PaikS., PegramM.D., PerezE.A., PressM.F., RhodesA., SturgeonC., TaubeS.E., TubbsR., VanceG.H., van de VijverM., WheelerT.M., HayesD.F.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med, 131: 18–43, 2007.
9.
KaplanE.L., MeierP.: Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53: 457–481, 1958.
10.
Gómez-RaposoC., Zambrana TévarF., Sereno MoyanoM., López GómezM., CasadoE.: Male breast cancer. Cancer Treat Rev, 36: 451–457, 2010.
11.
KordeL.A., ZujewskiJ.A., KaminL., GiordanoS., DomchekS., AndersonW.F., BartlettJ.M., GelmonK., NahlehZ., BerghJ., CutuliB., PruneriG., McCaskill-StevensW., GralowJ., HortobagyiG., CardosoF.: Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol, 28: 2114–2122, 2010.
12.
AltekruseS.F., KosaryC.L., KrapchoM., NeymanN., AminouR., WaldronW., RuhlJ., HowladerN., TatalovichZ., ChoH., MariottoA., EisnerM.P., LewisD.R., CroninK., ChenH.S., FeuerE.J., StinchcombD.G., EdwardsB.K.: November 2009 SEER data submission, posted to the SEER web site, 2010. SEER Cancer Statistics Review, 1975–2007, National Cancer Institute. Bethesda, MD. Available at http://seer.cancer.gov/csr/1975_2007/
13.
KilukJ.V., LeeM.C., ParkC.K., MeadeTMPH, MintonS., HarrisE., KimJ., LarongaC.: Male breast cancer: management and follow-up recommendations. Breast J, 17: 503–509, 2011.
14.
BratmanS.V., KappD.S., HorstK.C.: Evolving trends in the initial locoregional management of male breast cancer. Breast, 21: 296–302, 2012.
15.
De CiccoC., BaioS.M., VeronesiP., TrifiròG., CiprianA., VentoA., RososchanskyJ., VialeG., PaganelliG.: Sentinel node biopsy in male breast cancer. Nucl Med Commun, 25: 139–143, 2004.
16.
GennariR., CuriglianoG., Jereczek-FossaB.A., ZurridaS., RenneG., IntraM., GalimbertiV., LuiniA., OrecchiaR., VialeG., GoldhrischA., VeronesiU.: Male breast cancer: a special therapeutic problem. Anything new? Int J Oncol, 24: 663–670, 2004.
17.
RibeiroG., SwindellR.: Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer, 65: 252–254, 1992.
18.
GossP.E., ReidC., PintilieM., LimR., MillerN.: Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer, 85: 629–639, 1999.
19.
DoyenJ., ItalianoA., LargillierR., FerreroJ.M., FontanaX., ThyssA.: Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol, 21: 1243–1245, 2010.
20.
BagleyC.S., WesleyM.N., YoungR.C., LippmanM.E.: Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol, 10: 55–60, 1987.
21.
NCCN (National Comprehensive Cancer Network)Breast Cancer Guidelines.http://www.nccn.org
22.
EssermanL.J., MooreD.H., TsingP.J., ChuP.W., YauC., OzanneE., ChungR.E., TandonV.J., ParkJ.W., BaehnerF.L., KrepsS., TuttA.N., GillettC.E., BenzC.C.: Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat, 129: 607–616, 2011.
